INTRODUCTION

Infection with *H. pylori* infection has been recognized as a public health problem worldwide, affecting approximately 50% of the world population and more prevalent in developing than the developed countries. It is a common infection in diabetic patients who have inadequate metabolic control as such individuals are colonized by *H. pylori* infection in the gastric antrum, probably because of chemotactic factors such as TNF, Interleukins - IL1, IL2 and IL8 are present in gastric epithelium. These cytokines induce a number of changes in the gastric epithelium that promote inflammation and epithelial damage thus leading to increased risk of aberrant repair giving the picture of gastric atrophy or epithelial cell metaplasia.

Diabetes mellitus is one of the important causes of dyspepsia. Disordered gastrointestinal motor function is now recognized as a major problem of diabetes mellitus. Besides diabetes mellitus, *H. pylori* is also a well-established cause of dyspepsia. Incidence of *H. pylori* is increased in diabetes mellitus. Delayed gastric emptying and dysmotility are important causes of dyspepsia in diabetes. The role of *H. pylori* infection in diabetic dyspepsia is mainly related to blood glucose
concentration. Hyperglycemia may induce the infection by *H. pylori* or the silent infection may get reactivated and produce symptoms of dyspepsia in diabetes. *H. pylori* is also considered as an important risk factor both for gastric cancer and lymphomas.³

The prevalence of *H. pylori* in diabetes mellitus is 61%.⁴ Whereas the prevalence of *Helicobacter pylori* is 49% in non-diabetics.⁵ Diabetes is diagnosed according to the diagnostic criteria for the diabetes mellitus.⁶

Diagnostic tool for *H. pylori* infection are serology, endoscopic biopsy, histopathology, rapid urease test, urea breath test, PCR for DNA of *H. pylori*, *H. pylori* stool antigen (HPSA).

Endoscopic biopsy test is an invasive procedure with an overall specificity and sensitivity of 94%. Among various diagnostic methods, histology plays a pivotal role in detecting *H. pylori*.

Hyperglycemia is controlled by insulin or oral hypoglycemic drugs, while the drug used for eradication of *H. pylori* infection are proton pump inhibitors, bismuth compounds, metronidazole, clarithromycin, amoxicillin and tetracycline.⁷

Since there are only a few studies in our country on the association of *H. pylori* and diabetes mellitus with dyspeptic symptoms, we conducted this study at tertiary care teaching hospital.

The study focus is on the frequency of *H. pylori* infection in patients with type 2 diabetes mellitus with dyspeptic symptoms and non-diabetic with dyspeptic symptoms and help in providing data that is useful in the field of medicine as well as epidemiology.

**METHODS**

This case-control study was carried out in the Department of General Surgery at Saveetha Medical College and Hospital (a tertiary care hospital) Chennai, Tamilnadu from March 2016 to November 2016.

**Inclusion criteria**

- All patients above 35 years of age
- Both gender
- History of dyspepsia, bloating or epigastric discomfort for more than one month
- Known case of type 2 diabetes mellitus of ≥5 years duration and with poor glycemic control of HbAIC 7 or >7
- History of dyspepsia
- Epigastric discomfort, or bloating for ≥30 days.

**Exclusion criteria**

- Patients of type-I diabetes
- Non-cooperative patients who refuse to give consent or participate in the study
- Patients already on/had *H. pylori* eradication therapy.

The inclusion criteria of study were then investigated for diabetes (if not known) and *Helicobacter pylori* infection, and divided in to two groups: A and B.

Group A (also labelled diabetic group) contains patients of type II diabetes mellitus with dyspeptic symptoms (newly diagnosed or known cases) with positive or negative *Helicobacter pylori* infection while group B (also labelled non-diabetic group) contains non-diabetic individuals with dyspeptic symptoms with positive or negative *Helicobacter pylori* infection. Each group (A and B) consists of 98 patients.

The known cases of diabetes mellitus in group A were also investigated for blood sugar (not for diagnostic purpose but to assess the blood sugar level that whether it is controlled or uncontrolled).

**Data collection procedure**

- For the assessment of diabetes mellitus, we had taken venous blood sample and send to laboratory for fasting blood sugar (FBS) level, post-prandial blood sugar (PPBS) level and HbA1C.
- For detection of *Helicobacter pylori* infection, we advised the participants for endoscopic biopsy and sent to laboratory for detection of *Helicobacter pylori* organism.
- The collected data of both groups (A and B) were then evaluated, separated and saved for analysis.

**Data analysis:**

The data were evaluated in statistical program SPSS version 17. Frequency and percentages were calculated. The data were expressed by mean±SD of age and was computed among the numerical parameters. The chi-square test was applied among the categorical variables. The P value <0.01 was considered as statistically significant.

**RESULTS**

Ninety-eight patients in each group were studied, of which 113 (57.7%) were males and 83 (42.3%) females, mean age±SD, 50.04±11.78. Majority of the patients were more than 46 years of age (Table 1). The frequency of patients in relation to age group is mentioned in Figure 1.

In the diabetic group with dyspeptic symptoms, H. Pylori was positive in 70/98 (71.4%) cases while in non-diabetics, H. Pylori was positive in 51/98 (52%) cases (Table 2). Majority of the *H. pylori* infected patients in both groups were more than 46 years of age (Table 3).
Table 1: Demographic distribution of patients (n=196).

| Characteristics | N (%) |
|-----------------|-------|
| Gender          |       |
| Male            | 113 (57.7) |
| Female          | 83 (42.3)  |
| Endoscopic biopsy results of *H. pylori* |       |
| Positive        | 121 (61.7) |
| Negative        | 75 (38.3)  |
| Age group       |       |
| 35 to 45        | 81 (41.3)  |
| 46 to 55        | 54 (27.6)  |
| 56 to 65        | 38 (19.4)  |
| >65 years       | 23 (11.7)  |

Table 2: Frequency of endoscopic biopsy *Helicobacter pylori* positive cases in diabetic and non-diabetic group.

| Parameter                      | Endoscopic biopsy results of *H. pylori* (n=196) | P Value |
|--------------------------------|-----------------------------------------------|---------|
|                                | Diabetic (N=98%) | Non-diabetic (N=98%) |
| Endoscopic biopsy results of *H. pylori* |       |                   |
| Positive                       | 70 (71.4%) | 51 (52.0%) | 0.005** |
| Negative                       | 28 (28.6%) | 47 (48.0%) |       |

**P<0.01, P Value is statistically highly significant.

Table 3: Frequency of endoscopic biopsy *helicobacter pylori* positive cases in relation to age.

| Parameter | Endoscopic biopsy results of *Helicobacter pylori* positive cases (N=196) | P Value |
|-----------|--------------------------------------------------------------------------|---------|
| Age group | Positive (N=121) | Negative (N=75) |
| 35 to 45  | 54 (44.6%) | 27 (36.0%) | 0.417 (NS) |
| 46 to 55  | 29 (24.0%) | 25 (33.3%) |       |
| 56 to 65  | 25 (20.7%) | 13 (17.3%) |       |
| >65 years | 13 (10.7%) | 10 (13.3%) |       |

NS (Not Significant)

**DISCUSSION**

Patient with diabetes mellitus are often affected by chronic infections. Many studies have evaluated the prevalence of *H. pylori* infection in diabetic patients and the possible role of this condition in their metabolic control. Some studies found a higher prevalence of the infection in diabetic patients while others did not support any correlation between metabolic control and *H. pylori* infection. The present study determined the relationship between type 2 diabetes mellitus with dyspeptic symptoms and *Helicobacter pylori* infection and found that diabetic patients are most prone to acquire *H. pylori* infection (P = < 0.01) (statistically significant); However, higher prevalence of *H. pylori* infection was also reported in diabetes mellitus than in non-diabetics in a study by marrollo. In the present study majority of the patients with *H. pylori* infection in both groups: diabetic and non-diabetic, were more than 46 years of age. Similarly, a study conducted at Abakaliki by Ugwu had shown that majority of *Helicobacter pylori* infected patients were more than 60 years of age. However, a study by Sargyn et al, shows that mean age of diabetic patients with *H. pylori* infection is 56 years. Most of the *Helicobacter pylori* related diseases are associated with male gender, the role of gender as a risk factor for *H. pylori* infection is still debated. The present study shows that the *Helicobacter pylori* infections were common among males while another study conducted by Catherine confirms the male predominance of *H. pylori* infection in adults as a global and homogenous phenomenon. On the other hand, in another study the
Helicobacter pylori infected females were predominant as compared to males, and that contradicts our statement.13

H. pylori infection and H. pylori related gastrointestinal/gastroduodenal disorder may be related to glycemic status.

Wu et al have hypothesized that lack of H. pylori infection, especially during childhood, might enhance the risk of development of morbid obesity (a known risk factor for diabetes mellitus) based on the finding of inverse relationship between morbid obesity and H. pylori infection.14

Regarding the diagnostic tool used in this study for the detection of Helicobacter pylori infection, we preferred and used endoscopic biopsy test because it has high sensitivity (94%) and high specificity (94%) and is potentially very helpful in diagnosing H. pylori infection. In the present study, the majority of patients with Helicobacter pylori infection were between 46-85 years of age.

The present study detects that hyperglycemia is a risk factor for Helicobacter Pylori infection. The Hisayama study by, Yamagata et al, shows that hyperglycemia is a possible cofactor increasing the risk posed by H. pylori infection.15

CONCLUSION

Overall, the present study suggests that type 2 diabetic patients with dyspeptic symptoms are at more risk for H. pylori infection in comparison to non-diabetic population with dyspeptic symptoms, so every diabetic patient with acid peptic disorder must be screened for H. pylori. So, there is a need to provide proper counselling, education and awareness regarding diabetes mellitus and its association with H. pylori infection. Effective and appropriate measures should be taken against control of diabetes mellitus, eradication of H. pylori infection.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the institutional ethics committee

REFERENCES

1. Bener A, Micallef R, Afifi M, Derbala M, Al-Mulla HM, Usmani MA. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol. 2007;18:225-9.
2. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995;9:33-9.
3. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev. 1997;10:720-41.
4. Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycaemic control and late complications. Dig Dis Sci. 2008;53:2646-9.
5. Zuman R. Prevalence of Helicobacter pylori in relation to promotive factor among human urban population of Bahawalpur district Pakistan. Pak J Biol Sci. 2006;9:2636-41.
6. Engelgau MM. Diabetes diagnostic criteria and impaired glycemic states: evolving evidence base. Clin Diabetes. 2004;22:69-70.
7. Romano M, Cuomo A. Eradication of Helicobacter pylori: a clinical update. Med Gen Med. 2004;6:16-20.
8. Ojetti V, Migonec A, Silveri NG, Ghirlanda G, Gasbarrini G, Gasbarrini A. The role of H. pylori infection in Diabetes. Curr Diabetes Rev. 2005;1:343-7.
9. Marrollo M, Latella G, Melideo D, Storelli E, Iannarelli R, Stornellip, et al. Increased prevalence of Helicobacter pylori in patients with diabetes mellitus. Dig Liver Dis. 2001;33:21-9.
10. Ugwu N, Ugwuja E, Ejikemee B, Obeka N, Helicobacter pylori seropositivity in Nigerians with Type 2 Diabetes mellitus. Internet J Trop Med. 2008;4:32-6.
11. Sargyn M, Uygur-Bayramici O, Sargyn H, Orbay E, Yavuzer D, Yayla A. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol. 2003;9:1126-8.
12. De Martel C, Parsonnet J. Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys. Dig Dis Sci. 2006;51:2292-301.
13. Kanbay M, Gür G, Arslan H, Yilmaz U, Boyacioglu S. The relationship of ABO blood group, age, gender, smoking and Helicobacter pylori infection. Dig Dis Sci. 2005;50:1214-7.
14. WU MS, Lee WJ, Wang HH, Huang SP, Lin JT. A case-controlled study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med. 2005;165:1552-5.
15. Yamagata H, Kiyohara Y, Nakamura S, Kubo M, Tanizaki Y, Matsumoto T, et al. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population. The Hisayama Study. Diabetes Care. 2005;28:789-94.

Cite this article as: Rajesh S, Reshma S, Kamal SV. Helicobacter pylori risk in type 2 diabetes mellitus: a hospital based case-control study. Int Surg J 2017;4:3419-22.